

**PENN**  
UROLOGY

 Penn Medicine

ABRAMSON CANCER CENTER

# My surgery for kidney cancer

Thomas J. Guzzo, MD, MPH

Chief, Division of Urology



Associate Professor of Surgery (Urology)

University of Pennsylvania Healthy System

# Kidneys

**Figure 1**  
**The kidneys and urinary system**

The kidneys are a pair of organs in the abdomen. The kidneys are the main organs of the urinary system. They filter waste out of blood and make urine. The ureters, bladder, and urethra hold and transport urine before it is released from the body.



# Kidney cancer



**Malignant cell growth (a tumor) in the kidneys**


# Renal mass vs. kidney cancer vs. renal cell carcinoma (RCC)

- Not all renal masses are cancer, but most of them are (~ 85%)
- Bigger mass = more likely cancer
- Most kidney cancer called RCC

Tumor Size (cm)	No. Benign (%)	No. RCC (%)
0.0–Less than 1.0	37 (46.3)	43 (53.8)
1.0–Less than 2.0	38 (22.4)	132 (77.7)
2.0–Less than 3.0	75 (22.0)	266 (78.0)
3.0–Less than 4.0	71 (19.9)	285 (80.1)
4.0–Less than 5.0	37 (9.9)	336 (90.1)
5.0–Less than 6.0	40 (13.0)	267 (87.0)
6.0–Less than 7.0	11 (4.5)	232 (95.5)
7.0 or Greater	67 (6.3)	998 (93.7)



Percentages indicate the proportion of tumors in each size category that are benign or RCC, respectively.

**Renal Cell Carcinoma (RCC)**  
About 9 out of 10 kidney cancers are RCCs.



# Incidence in United States



- The incidence of kidney cancer has been increasing steadily since the 1970's (USA)
- Due to more prevalent use of axial imaging (CT/MRI)
- Continue to increase over last decade, about 1% per/year (USA)






# Kidney cancer demographics, 2019

## Estimated New Cases

			Males	Females			
Prostate	174,650	20%			Breast	268,600	30%
Lung & bronchus	116,440	13%			Lung & bronchus	111,710	13%
Colon & rectum	78,500	9%			Colon & rectum	67,100	8%
Urinary bladder	61,700	7%			Uterine corpus	61,880	7%
Melanoma of the skin	57,220	7%			Melanoma of the skin	39,260	4%
<b>Kidney &amp; renal pelvis</b>	<b>44,120</b>	<b>5%</b>			Thyroid	37,810	4%
Non-Hodgkin lymphoma	41,090	5%			Non-Hodgkin lymphoma	33,110	4%
Oral cavity & pharynx	38,140	4%			<b>Kidney &amp; renal pelvis</b>	<b>29,700</b>	<b>3%</b>
Leukemia	35,920	4%			Pancreas	26,830	3%
Pancreas	29,940	3%			Leukemia	25,860	3%
<b>All Sites</b>	<b>870,970</b>	<b>100%</b>			<b>All Sites</b>	<b>891,480</b>	<b>100%</b>



- Male: 6th most common cancer diagnosis
- Female: 7th most common cancer diagnosis
- Male > Female 2:1
- Most frequently diagnosed at age 55-74
- Median age at diagnosis: 64
- About 14,770 people (9,820 men and 4,950 women) will die from this disease


# Kidney cancer diagnosis

- Most kidney cancers are found by chance during imaging tests for other health problems
- Majority asymptomatic
- About 1 in 10 people do experience symptoms like pain in the side of the body, abdominal mass or blood in the urine
- Bone pain or a persistent cough could be signs that the cancer has spread through the body. This is known as metastatic disease

# Size is important


**Figure 5**  
Kidney tumors are measured in centimeters

A baseball is 7 cm, a golf ball is 4 cm, and a pea is 1 cm.







# Stages of kidney cancer (TNM staging)




**T Stage 1**  
Tumor  $\leq 7$  cm  
confined to kidney



**T Stage 2**  
Tumor  $> 7$  cm  
confined to kidney




**T Stage 3**  
Spread into renal vein,  
perirenal fat, or the  
vena cava




**T Stage 4**  
Spread beyond renal  
fascia and into the  
adrenal gland

# Stages of kidney cancer (TNM staging)



**N0 - No metastasis in lymph node**

**N1 - Metastasis in regional lymph node**



**M0 - No distant metastasis**

**M1 - Distant metastasis**

**Lung (75%)**

**Soft tissues (36%)**

**Bone (20%)**

**Liver (18%)**

**Cutaneous sites (8%)**

**CNS (8%)**


# Stages of kidney cancer (TNM staging)

Majority


Stage	Primary tumor (T)	Regional lymph nodes (N)	Distant metastasis (M)
<b>Stage I</b>	<b>T1</b> Tumor is 7 cm or smaller and found only in kidney	<b>N0</b> There is no cancer in nearby lymph nodes	<b>M0</b> Cancer has not spread to other parts of the body
<b>Stage II</b>	<b>T2</b> Tumor is larger than 7 cm and found only in the kidney	<b>N0</b>	<b>M0</b>
<b>Stage III</b>	<b>T1 or T2</b>	<b>N1</b> There is cancer (metastasis) in nearby lymph nodes	<b>M0</b>
	<b>T3</b> Tumor has grown outside the kidney into major veins and tissues, but not into Gerota's fascia	<b>N0 or N1</b>	<b>M0</b>
<b>Stage IV</b>	<b>T4</b> Tumor has grown beyond Gerota's fascia	<b>Any N</b>	<b>M0</b>
	<b>Any T</b>	<b>Any N</b>	<b>M1</b> Cancer has spread to other parts of body (metastasized)

# Stage migration

- The greatest increase in incidence has been in small, clinically localized kidney cancers (Stage I [T1N0M0])
- The size of stage I cancers decreases



**FIGURE 1.** Renal cell carcinoma (RCC) stage distribution by diagnosis year.



# Survival and cancer stages

**TABLE 57-10** Tumor, Node, Metastasis (TNM) Stage and 5-Year Survival for Renal Cell Carcinoma

FINDINGS	ROBSON STAGE	TNM (2002)	TNM (2009)	5-YEAR SURVIVAL (%)
Organ-confined (overall)	I	T1-2N0M0	T1-2N0M0	70-90
≤4.0 cm	I	T1aN0M0	T1aN0M0	90-100
>4.0 cm to 7.0 cm	I	T1bN0M0	T1bN0M0	80-90
>7.0 to 10.0 cm	I	T2N0M0	T2aN0M0	65-80
>10.0 cm	I	T2N0M0	T2bN0M0	50-70
Invasion of perinephric or renal sinus fat	II	T3aN0M0	T3aN0M0	50-70
Invasion of renal vein or branches	IIIA	T3bN0M0	T3aN0M0	40-60
Invasion of IVC below diaphragm	IIIA	T3cN0M0	T3bN0M0	30-50
Invasion of IVC above diaphragm or invasion of IVC wall	IIIA	T3cN0M0	T3cN0M0	20-40
Direct adrenal involvement	II	T3aN0M0	T4N0M0	0-30
Locally advanced (invasion beyond Gerota fascia)	IVA	T4N0M0	T4N0M0	0-20
Lymph node involvement	IIIB	(Any)TN1-2M0	(Any)TN1M0	0-20
Systemic metastases	IVB	(Any)T(Any)NM1	(Any)T(Any)NM1	0-10

IVC, inferior vena cava.

Data from Hafez et al, 1999; Leibovich et al, 2005a; Thompson et al, 2005a; Lane and Kattan, 2008; Campbell et al, 2009; Martinez-Salamanca et al, 2011; and Haddad and Rini, 2012.

# Kidney cancer treatment

- **Surgery**
- Active surveillance
- Thermal ablation
- Targeted therapy
- Immunotherapy
- Clinical trials




- Cancer stages
- Cancer complexities
- General health
- Your preferences for treatment

**Surgery is the main treatment for the majority of kidney cancers, with the goal of removing the tumor and preserving normal kidney function.**




# Surgical treatment

Stage	Surgery	Approach	Recommendations
T1	Nephron-sparing surgery	Open Laparoscopic/Robotic	Recommended standard Optional in experienced centres
	Radical nephrectomy		In patients not suitable for nephron-sparing surgery
T2	Radical nephrectomy	Laparoscopic/Robotic	Recommended standard
	Nephron-sparing surgery		Recommended in selected patients in experienced centres
T3, T4	Radical nephrectomy	Open Laparoscopic/Robotic	Recommended standard for most patients Feasible in selected patients




**Radical nephrectomy**




**Partial nephrectomy**

# My surgery for kidney cancer



# My experiences

- Medical School: Temple University School of Medicine
- Residency (Urology): Hospital of the University of Pennsylvania
- Fellowship (Urologic Oncology): Johns Hopkins Hospital
- Faculty at Penn Medicine since 2009
- Focusing on surgical treatment, especially minimally-invasive surgery for kidney, prostate, bladder, testicular and other urologic cancers




# Small kidney tumors



**Robot-assisted partial nephrectomy**

## Management of Small Kidney Tumors

Tumors in the kidney measuring 4 cm or less are unlikely to rapidly grow or spread to other parts of the body.




### Treatment options

#### Active surveillance

Regular observation of the tumor to determine if it grows


#### Partial nephrectomy

Surgical removal of the tumor and surrounding healthy tissue



#### Percutaneous ablation

Freezing (cryoablation) or heating (radiofrequency ablation) of the tumor



#### Radical nephrectomy

Surgical removal of the entire kidney, nearby adrenal gland, and lymph nodes

# Robot-assisted partial nephrectomy (RAPN)


## Systematic Review and Meta-analysis of Comparative Studies Reporting Perioperative Outcomes of Robot-Assisted Partial Nephrectomy Versus Open Partial Nephrectomy

Leilei Xia, MD,<sup>1</sup> Xianjin Wang, MD,<sup>2</sup> Tianyuan Xu, MD,<sup>2</sup> and Thomas J. Guzzo, MD, MPH<sup>1</sup>



- Equivalent oncologic and functional outcomes
- Less blood loss
- Fewer complications
- Reduced pain and discomfort
- Shorter hospitalization
- Faster recovery time and return to normal activities
- Smaller incisions, resulting in reduced risk of infection
- Better cosmetic appearance

# What are the advantages




- Immersive high-definition 3-D visualization
- Enhanced dexterity, fully articulating instruments
- Greater precision, intuitive computer-enhanced motion control

Surgeons can perform delicate and complex procedures that may have been difficult or impossible with other methods, such as partial nephrectomy




# How it is done




When performing robotic surgery using the da Vinci Surgical System:

- The surgeon works from a computer console in the operating room, controlling miniaturized instruments mounted on three robotic arms to make tiny incisions in the patient.
- The surgeon looks through a 3-D camera attached to a fourth robotic arm, which magnifies the surgical site.
- The surgeon's hand, wrist and finger movements are transmitted through the computer console to the instruments attached to the robot's arms. The mimicked movements have the same range of motion as the surgeon allowing maximum control.
- The surgical team supervises the robot at the patient's bedside.



# Robot-assisted partial nephrectomy



No cancer recurrence since 2016

# Intraoperative imaging at Penn

Penn Medicine

ABRAMSON CANCER CENTER

About | Why Penn? | Giving | Locations | t

Types of Cancer ▾ Navigating Cancer Care ▾ Cancer Research ▾

Search


Navigating Cancer Care

Programs & Centers

Center for Precision Surgery

Request an Appointment >

Find a Clinical Trial >




**Program Overview**

Penn's Medicine's Center for Precision Surgery brings together a team of surgeons, oncologists, scientists and specialized nurses who work each day to provide patients with the latest and most advanced techniques in cancer surgery.

In most cases involving solid tumors, surgery is one of the key components to treatment success. A common challenge, however, is that the surgeon may have limited views of the entire tumor making it difficult to remove all the diseased tissue.

Surgery Using Intraoperative Molecular Imaging



- **Mission Statement:** To improve the cancer care of surgery patients through intraoperative molecular imaging techniques
- 13 Surgeons (Thoracic, Urology, Neurosurgery, Surg Onc, Breast, ENT, Gyn Onc), 2 Staff PhDs, 10+ Active Clinical Trials , Over 500 patients enrolled




# Intraoperative imaging at Penn

## Investigative Urology

### Intraoperative Molecular Diagnostic Imaging Can Identify Renal Cell Carcinoma

Thomas J. Guzzo, Jack Jiang, Jane Keating, Elizabeth DeJesus, Ryan Judy, Shuming Nie, Philip Low, Priti Lal and Sunil Singhal


From the Departments of Surgery (TJG, JJ, JK, ED, RJ, SS) and Pathology (PL), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Departments of Biomedical Engineering and Chemistry, Emory University (SN), Atlanta, Georgia, and Department of Chemistry (PL), Purdue University, West Lafayette, Indiana



## Oncology


### Near-infrared Intraoperative Molecular Imaging Can Identify Metastatic Lymph Nodes in Prostate Cancer

Leilei Xia, Ryan Zeh, Jack Mizelle, Andrew Newton, Jarrod Predina, Shuming Nie, Sunil Singhal, and Thomas J. Guzzo



### Intraoperative Molecular Imaging for Post-Chemotherapy Robot-Assisted Laparoscopic Resection of Seminoma Metastasis: A Case Report

Leilei Xia,<sup>1,2</sup> Ollin G. Venegas,<sup>2,3</sup> Jarrod D. Predina,<sup>2,3</sup> Sunil Singhal,<sup>2,3</sup> Thomas J. Guzzo<sup>1,2</sup>



# Intraoperative imaging in RAPN


Curr Urol Rep (2015) 16: 20  
DOI 10.1007/s11934-015-0495-9

NEW IMAGING TECHNIQUES (A RASTINEHAD AND S RAIS-BAHRAMI, SECTION EDITORS)


## Near-Infrared Fluorescence Imaging with Intraoperative Administration of Indocyanine Green for Robotic Partial Nephrectomy

Marc A. Bjurlin · Tyler R. McClintock · Michael D. Stiefman

**Fig 1** NIRF imaging with ICG to facilitate optimization of renal tumor localization. Renal mass seen under white light (a) and under NIRF imaging with ICG demonstrating a hypofluorescent tumor adjacent to bright green normal renal parenchyma (b)




**Fig 2** NIRF imaging with ICG to facilitate selective arterial clamping. Dissection of the secondary, tertiary, or quaternary level arterial branches (a), selective arterial clamping with mini bulldog clamps seen under NIRF imaging with ICG (bright fluorescent green vessels) (b), renal tumor seen under white light (c), and NIRF imaging with ICG (hypofluorescent renal tumor confirming ischemia with perfused bright green normal renal parenchyma) (d)



Indocyanine green (ICG)



# Intraoperative imaging in RAPN




Folate receptor targeted dye OTL38




# Laparoscopic/robotic radical nephrectomy

- Mostly for large (>7 cm) and/or endophytic tumors that partial nephrectomy would be oncologically unsafe but can still be done in a minimally invasive manner
- Robot is better than conventional laparoscopy



# Open radical nephrectomy with or without thrombectomy

- For very large tumors with or without tumor thrombus in renal vein or inferior vena cava (IVC)
- Cancer control is priority, complete resection of the tumor and thrombectomy allow for the best chance of cure
- Sometimes involves other surgical teams
- High volume institution for RCC IVC thrombectomy




# Multidisciplinary surgical team



**Surgical  
Oncology**



**Urologic  
Oncology**



**Anesthesiology and Critical Care**



**Cardiac  
Surgery**




**Vascular  
Surgery**



# Cytoreductive nephrectomy

- Established management options for selected individuals with metastatic renal cell cancer (mRCC)
- Careful patient selection with multidisciplinary input is essential




# My surgery for kidney cancer

- Surgery is the main treatment for the majority of kidney cancers
- Most small kidney tumors/cancers can be surgically treated with robot-assisted partial nephrectomy
- Some larger tumors/cancers can still be done through minimally invasive approach, either partial nephrectomy or radical nephrectomy
- Open radical nephrectomy with or without thrombectomy are reserved for very large/complex cancers, multidisciplinary surgical team is often needed
- Cytoreductive nephrectomy is still recommended for certain patients



# Recommendations and References



# Thank you



**Hospital of the University of Pennsylvania**



**Perelman Center for Advanced Medicine**